Elective esophageal variceal ligation (EVL) is performed to decrease the risk of variceal hemorrhage. Side effects of EVL include hemorrhage, chest pain, dysphagia, and odynophagia. Because gastric acid may exacerbate postbanding ulcers and delay healing, proton pump inhibition may decrease side effects associated with EVL. The aim of this study was to assess the efficacy of pantoprazole, a proton pump inhibitor, as an adjunct to elective EVL. We performed a double-blinded, randomized, placebo-controlled trial of pantoprazole after elective EVL. Subjects in the pantoprazole arm received 40 mg pantoprazole intravenously after EVL followed by 40 mg oral pantoprazole for 9 days. Control subjects received intravenous and oral placebo. Subjects underwent upper endoscopy 10 to 14 days after banding. Primary outcomes included the size and number of ulcers and the subjects' reports of dysphagia, chest pain, and heartburn. Forty-four subjects were randomized: 42 completed the protocol. At follow-up endoscopy, the mean number of ulcers was similar in the two groups. However, the ulcers in the pantoprazole group were on average half as large as in the placebo group (37 mm 2 vs. 82 mm 2 , P < .01). Chest pain, dysphagia, and heartburn scores were not significantly different. Four subjects, all in the placebo group, had adverse outcomes, including 3 who bled from postbanding ulcers and 1 with sepsis. In conclusion, subjects receiving pantoprazole after elective EVL had significantly smaller postbanding ulcers on follow-up endoscopy than subjects receiving placebo. However, the total ulcer number and patient symptoms were not different between the groups. (HEPATOLOGY 2005;41: 588-594.)

In this cohort of young women with rheumatologic disease, more women with prior CYC than without had amenorrhea, nulliparity, and infertility. GnRH-a co-therapy may prevent these adverse effects of CYC.

Objective The recent recognition of the correlation of the hip-knee-ankle angle (HKA) with femur-tibia angle (FTA) on a standard knee radiograph has led to the increasing inclusion of FTA assessments in OA studies due to its clinical relevance, cost effectiveness and minimal radiation exposure. Our goal was to investigate the performance metrics of currently used methods of FTA measurement to determine whether a specific protocol could be recommended based on these results. Methods Inter- and intra-rater reliability of FTA measurements were determined by intraclass correlation coefficient (ICC) of two independent analysts. Minimal detectable differences were determined and the correlation of FTA and HKA was analyzed by linear regression. Differences among methods of measuring HKA were assessed by ANOVA. Results All five methods of FTA measurement demonstrated high precision by inter- and intra-rater reproducibility (ICCs≥0.93). All five methods displayed good accuracy, but after correction for the offset of FTA from HKA, the femoral notch landmark method was the least accurate. However, the methods differed according to their minimal detectable differences; the FTA methods utilizing the center of the base of the tibial spines or the center of the tibial plateau as knee center landmarks yielded the smallest minimal detectable differences (1.25° and 1.72° respectively) Conclusion All methods of FTA were highly reproducible, but varied in their accuracy and sensitivity to detect meaningful differences. Based on these parameters we recommend standardizing measurement angles with vertices at the base of the tibial spines or the center of the tibia and comparing single-point and two-point methods in larger studies.

No abstract

Pregnancy can create a challenge for physicians caring for women with rheumatic diseases. For many women with rheumatoid arthritis (RA), pregnancy can provide a reprieve from long-term joint pain and inflammation, but others will not experience remission and will continue to need medication. Systemic lupus erythematosus (SLE) may remain quiet in some women, but in others may become more aggressive during pregnancy, putting both mother and foetus at risk. Women with limited scleroderma can do remarkably well, but scleroderma renal crises can be difficult to manage. A third of pregnancies in women with antiphospholipid syndrome (APS) may be refractory to our best therapy. In general, active inflammation from rheumatic diseases poses a stronger threat to the well-being of both mother and foetus than many immunosuppressant medications. Therefore, continued immunosuppression with the least risky medications will allow for the most optimal pregnancy outcomes.